-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on OnKure Therapeutics, Lowers Price Target to $21

Benzinga·07/20/2026 15:52:43
Listen to the news
HC Wainwright & Co. analyst Robert Burns maintains OnKure Therapeutics (NASDAQ:OKUR) with a Buy and lowers the price target from $27 to $21.